We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KEYS:NYSEKeysight Technologies Inc. Analysis

Data as of 2026-06-14 - not real-time

$350.67

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Keysight Technologies (KEYS) is trading at $350.67, comfortably above its 20‑day ($340.92) and 50‑day ($339.55) SMAs and well above the 200‑day SMA ($242.66), confirming a bullish price structure. The RSI of 55 indicates neutral momentum while the MACD remains bearish, suggesting short‑term consolidation despite the overall bullish trend. Revenue surged 31.5% YoY to $6.09 B with a robust gross margin of 62% and operating margin of 19%, driving EPS growth from $6.21 to an estimated $11.86 forward. However, the current price reflects a PE of 56.5 versus an industry average of 36.8, and the DCF‑derived fair value of $228.16 implies the stock is priced well above intrinsic value. The market sentiment is extremely bullish (Fear/Greed Index 89.86 – “Extreme Greed”), yet volatility remains high at 37.9% over 30 days and beta exceeds 1.7, flagging elevated systematic risk. Recent earnings calls highlighted record orders in AI‑driven data‑center and defense segments, providing strong growth catalysts, but decreasing volume and a bearish MACD caution against a rapid breakout.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price is near support at $315 and below resistance $359, indicating limited upside
  • Bearish MACD histogram signals potential short‑term pullback
  • Strong earnings beat and record order flow provide a cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained revenue growth >30% YoY driven by AI data‑center and defense demand
  • Forward PE of 29.6 narrows the valuation gap
  • Technical alignment above key moving averages supports continued uptrend

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Current market price exceeds DCF fair value, implying a valuation premium
  • High beta and volatility increase exposure to market cycles
  • Strong cash position and ROE (~18%) underpin financial resilience

Key Metrics & Analysis

Financial Health

Revenue Growth31.50%
Profit Margin17.31%
P/E Ratio56.5
ROE18.17%
ROA6.04%
Debt/Equity43.64
P/B Ratio9.5
Op. Cash Flow$1.5B
Free Cash Flow$1.1B
Industry P/E36.8

Technical Analysis

TrendBullish
RSI55.6
Support$315.01
Resistance$359.05
MA 20$340.92
MA 50$339.55
MA 200$242.66
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value$228.16
Target Price$383.08
Upside/Downside9.24%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.77
Volatility37.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.